Protara Therapeutics, Inc. TARA 深 滬

美股大行评级 | 瑞银：维持Visa"买入"评级！目标价从390美元升至410美元

今日重点评级关注：HC Wainwright & Co.：维持Protara Therapeutics"买入"评级，目标价从23美元升至27美元；BTIG：维持Black Diamond Therapeutic"买入"评级，目标价从10美元升至11美元

04-30 19:24

Protara Therapeutics To Demonstrate Interim Data From Cohort A Of Its Current Phase 2 Open-Label ADVANCED-2 Study Of TARA-002 In Participants With BCG-Naïve Non-Muscle Invasive Bladder Cancer At American Urological Association 2026 Annual Meeting

Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data

04-28 04:10

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

04-27 20:05

Protara Therapeutics GAAP EPS of -$0.37

Protara Therapeutics press release (TARA): Q4 GAAP EPS of -$0.37. As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proce...

03-11 03:11

Protara Q4 net loss widens on higher R&D spend

Protara Q4 net loss widens on higher R&D spend Overview Biotechnology firm's Q4 net loss was $17.3 mln, driven by increased R&D expenses Company completed $86 mln public offering, cash supports operations into 2028 Outlook Protara to provide regulatory update for TARA-002 in LMs in 1H 2026 Result Dr

03-10 20:07

Protara Therapeutics Q4 EPS $(0.37) Misses $(0.33) Estimate

Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 22.92 percent increase over losses of $(0.48) per share

03-10 20:03

BRIEF-Protara Therapeutics Q4 EPS USD -0.37

BRIEF-Protara Therapeutics Q4 EPS USD -0.37 Mar 10 (Reuters) - Protara Therapeutics Q4 operating expenses USD 19.079 million. Q4 income from operations USD -19.079 million Q4 net income USD -17.307 million

03-10 20:00

美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价

今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元

03-05 13:56

JP Morgan Initiates Coverage On Protara Therapeutics with Overweight Rating, Announces Price Target of $27

JP Morgan analyst Brian Cheng initiates coverage on Protara Therapeutics (NASDAQ:TARA) with a Overweight rating and announces Price Target of $27.

03-04 20:35

U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials

U.S. RESEARCH ROUNDUP-Crowdstrike, Oracle, Vulcan Materials March 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Crowdstrike, Oracle and Vulcan Materials, on Wednesday. HIGHLIGHTS * Crowdstrike CRWD.O : Bernstein rais

03-04 17:14